Free Trial

Enlivex Therapeutics (ENLV) Competitors

Enlivex Therapeutics logo
$1.08 +0.02 (+1.41%)
Closing price 09/16/2025 04:00 PM Eastern
Extended Trading
$1.08 +0.00 (+0.46%)
As of 06:28 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ENLV vs. ANRO, ANEB, CNTB, CRVO, IPA, ANIX, ALTS, VIRI, ENTX, and ORMP

Should you be buying Enlivex Therapeutics stock or one of its competitors? The main competitors of Enlivex Therapeutics include Alto Neuroscience (ANRO), Anebulo Pharmaceuticals (ANEB), Connect Biopharma (CNTB), CervoMed (CRVO), ImmunoPrecise Antibodies (IPA), Anixa Biosciences (ANIX), ALT5 Sigma (ALTS), Virios Therapeutics (VIRI), Entera Bio (ENTX), and Oramed Pharmaceuticals (ORMP). These companies are all part of the "pharmaceutical products" industry.

Enlivex Therapeutics vs. Its Competitors

Alto Neuroscience (NYSE:ANRO) and Enlivex Therapeutics (NASDAQ:ENLV) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, dividends, risk, profitability, valuation and earnings.

In the previous week, Alto Neuroscience had 17 more articles in the media than Enlivex Therapeutics. MarketBeat recorded 25 mentions for Alto Neuroscience and 8 mentions for Enlivex Therapeutics. Alto Neuroscience's average media sentiment score of 0.18 beat Enlivex Therapeutics' score of 0.15 indicating that Alto Neuroscience is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Alto Neuroscience
2 Very Positive mention(s)
0 Positive mention(s)
23 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Enlivex Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Alto Neuroscience presently has a consensus price target of $8.50, indicating a potential upside of 115.74%. Enlivex Therapeutics has a consensus price target of $10.00, indicating a potential upside of 825.93%. Given Enlivex Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Enlivex Therapeutics is more favorable than Alto Neuroscience.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alto Neuroscience
0 Sell rating(s)
3 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.57
Enlivex Therapeutics
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00

Alto Neuroscience's return on equity of -44.34% beat Enlivex Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Alto NeuroscienceN/A -44.34% -36.73%
Enlivex Therapeutics N/A -58.31%-50.32%

1.0% of Enlivex Therapeutics shares are owned by institutional investors. 12.3% of Enlivex Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Enlivex Therapeutics is trading at a lower price-to-earnings ratio than Alto Neuroscience, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alto NeuroscienceN/AN/A-$61.43M-$2.39-1.65
Enlivex TherapeuticsN/AN/A-$15.01M-$0.58-1.86

Alto Neuroscience has a beta of 1.91, indicating that its stock price is 91% more volatile than the S&P 500. Comparatively, Enlivex Therapeutics has a beta of 0.83, indicating that its stock price is 17% less volatile than the S&P 500.

Summary

Alto Neuroscience beats Enlivex Therapeutics on 7 of the 13 factors compared between the two stocks.

Get Enlivex Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ENLV and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ENLV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ENLV vs. The Competition

MetricEnlivex TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$25.19M$2.55B$5.73B$10.31B
Dividend YieldN/A60.31%5.90%4.63%
P/E Ratio-1.8623.4976.3826.51
Price / SalesN/A672.77521.37123.58
Price / CashN/A169.4937.1760.46
Price / Book1.085.3313.666.29
Net Income-$15.01M$32.95M$3.28B$270.51M
7 Day Performance6.40%0.10%0.88%1.95%
1 Month Performance-40.66%3.91%4.67%6.33%
1 Year Performance-28.48%-3.91%80.92%25.62%

Enlivex Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ENLV
Enlivex Therapeutics
2.5372 of 5 stars
$1.08
+1.4%
$10.00
+825.9%
-29.9%$25.19MN/A-1.8670
ANRO
Alto Neuroscience
2.74 of 5 stars
$3.91
+6.5%
$8.50
+117.4%
-71.7%$99.37MN/A-1.64N/A
ANEB
Anebulo Pharmaceuticals
2.1107 of 5 stars
$2.20
-7.6%
$5.50
+150.0%
+19.1%$97.78MN/A-8.464News Coverage
Upcoming Earnings
High Trading Volume
CNTB
Connect Biopharma
3.6958 of 5 stars
$1.79
+2.3%
$7.00
+291.1%
+36.4%$97.51M$26.03M0.00110News Coverage
Analyst Revision
Gap Up
CRVO
CervoMed
3.8201 of 5 stars
$9.99
-4.9%
$19.29
+93.1%
-49.9%$97.25M$9.74M-3.834Positive News
IPA
ImmunoPrecise Antibodies
2.6182 of 5 stars
$2.10
+8.5%
$4.00
+90.9%
+284.4%$96.68M$17.59M-3.0880Gap Up
ANIX
Anixa Biosciences
3.1194 of 5 stars
$2.98
+0.3%
$9.00
+202.0%
+9.1%$95.67M$210K-7.845Earnings Report
Analyst Revision
ALTS
ALT5 Sigma
0.1817 of 5 stars
$4.13
-5.9%
N/A+84.5%$94.97M$12.53M0.00170Gap Up
VIRI
Virios Therapeutics
N/A$4.90
-2.0%
$5.00
+2.0%
+2,379.8%$94.36MN/A-18.155
ENTX
Entera Bio
1.4839 of 5 stars
$2.00
-2.9%
$10.00
+400.0%
-9.5%$94.07M$180K-7.6920Positive News
High Trading Volume
ORMP
Oramed Pharmaceuticals
0.8523 of 5 stars
$2.30
+3.1%
N/A-7.7%$91.44M$1.34M-6.5710

Related Companies and Tools


This page (NASDAQ:ENLV) was last updated on 9/17/2025 by MarketBeat.com Staff
From Our Partners